- Home
- DYN vs APGE Comparison
DYN vs APGE Comparison
Compare DYN & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- APGE
- Stock Information
- Founded
- DYN 1984
- APGE 2022
- Country
- DYN United States
- APGE United States
- Employees
- DYN N/A
- APGE N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYN Health Care
- APGE Health Care
- Exchange
- DYN Nasdaq
- APGE Nasdaq
- Market Cap
- DYN 2.6B
- APGE 3.0B
- IPO Year
- DYN 2020
- APGE 2023
- Fundamental
- Price
- DYN $14.13
- APGE $37.06
- Analyst Decision
- DYN Strong Buy
- APGE Strong Buy
- Analyst Count
- DYN 10
- APGE 5
- Target Price
- DYN $50.70
- APGE $83.50
- AVG Volume (30 Days)
- DYN 1.8M
- APGE 488.2K
- Earning Date
- DYN 03-04-2025
- APGE 03-04-2025
- Dividend Yield
- DYN N/A
- APGE N/A
- EPS Growth
- DYN N/A
- APGE N/A
- EPS
- DYN N/A
- APGE N/A
- Revenue
- DYN N/A
- APGE N/A
- Revenue This Year
- DYN N/A
- APGE N/A
- Revenue Next Year
- DYN N/A
- APGE N/A
- P/E Ratio
- DYN N/A
- APGE N/A
- Revenue Growth
- DYN N/A
- APGE N/A
- 52 Week Low
- DYN $14.03
- APGE $31.75
- 52 Week High
- DYN $47.45
- APGE $72.29
- Technical
- Relative Strength Index (RSI)
- DYN 19.54
- APGE 32.29
- Support Level
- DYN $14.79
- APGE $36.48
- Resistance Level
- DYN $15.90
- APGE $42.98
- Average True Range (ATR)
- DYN 1.55
- APGE 2.92
- MACD
- DYN -0.82
- APGE -0.99
- Stochastic Oscillator
- DYN 0.82
- APGE 4.12
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.